TickerTalks
Browse all tickers →
TickerTalks›$AARD
AAAARD

Aardvark Therapeutics, Inc. Common Stock

$AARD·$173M·Biotechnology·Healthcare
$6.88+0.9%YTD-51.8%1Y-23.9%
Mentions · last 7 days
2026-08-18: 1 posts2026-08-19: 0 posts2026-08-20: 1 posts2026-08-21: 0 posts2026-08-22: 0 posts2026-08-23: 4 posts2026-08-24: 0 posts60%
Price updated 13h ago·X counts updated 12h ago
AAAARD
$AARDAardvark Therapeutics, Inc. Common Stock
$6.88+0.88%6 posts0%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $AARD, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Too early to tellSelling offAI verdict · as of 2026-08-21

Falling on heavy selling — points lower unless it turns around.

Nutrient-sensing biotech down 52% year-to-date with a fresh class action — a specific pipeline event has to land or the equity keeps drifting.

Aardvark Therapeutics is a clinical-stage biopharmaceutical developing small-molecule treatments that stimulate the body's nutrient-sensing pathways — a novel mechanism aimed at obesity, endocrine, and neuroinflammatory conditions. Pre-commercial; the equity is entirely tied to clinical progression.

  • Revenue is $0 and consensus 2026 revenue is a symbolic $300K — the equity story is entirely pipeline-optionality, and 2027 consensus at $1M steps up modestly.
  • Q2 EPS came in at -$0.66 vs -$0.87 consensus (a 25% surprise on burn less than modelled) — the burn is somewhat below expectations, though the ~$18M quarterly cash burn is substantial for a $173M market-cap company.
  • Stock is -52% year-to-date and -39% over 12 months, sitting at the 23rd percentile of the 52-week range and 18% below the 200-day trend — the tape has been in aggressive distribution for a year.
  • On Aug 20 SBS Law opened a securities-fraud lawsuit for losses between Feb 2025 and May 2026 — a specific class-action overhang that adds legal-exposure risk on top of the fundamental deterioration.

What restarts the move is a specific positive Phase 2 readout on the nutrient-sensing platform alongside a clean resolution of the class-action allegations. What confirms the breakdown is another quarter of accelerating cash burn or a specific clinical delay; at this cash-burn rate the equity will need a raise within the year that would materially dilute existing holders.

What to watch: Nov 12 Q3 earnings — cash-runway detail and any nutrient-sensing platform Phase 2 progression. Watch the class-action docket for specific alleged misstatements.

On the calendar: 2026-11-12 — Q3 earnings

Read the AI verdict + X sentiment for $AARD

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage biotech developing gut-targeted small molecules for metabolic disorders; lead drug ARD-101 is in Phase III for hyperphagia.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $AARD.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $AARD

Neutral — Clinical-stage biotech developing gut-targeted small molecules for metabolic disorders; lead drug ARD-101 is in Phase III for hyperphagia; limited read-through from biotechnology macro dynamics to this specific revenue mix.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+52.3%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-2.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-85.6%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-37.2%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-61.7%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 11, 2026$-0.66$-0.87+24.5%
Q1 2026May 7, 2026$-0.99$-0.88-12.9%
Q4 2025Mar 23, 2026$-0.81$-0.83+2.1%
Q3 2025Nov 13, 2025$-0.75$-0.80+6.1%
Next earningsThu, Nov 12·consensus EPS $-0.74

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.99$-18.9M
Q4 FY25$0———$-0.81$-14.4M
Q3 FY25$0———$-0.75$-18.5M
Q2 FY25$0———$-0.66$-9.9M

Forward consensus

5-year forecast · up to 10 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$300K$300K – $300K-$3.61-$4.56 – -$2.2810
FY27$1.0M$1.0M – $1.0M-$3.15-$4.54 – -$1.816
FY28$6.6M$6.6M – $6.6M-$2.93-$5.28 – -$1.447
FY29$89.0M$89.0M – $89.0M-$1.64-$1.64 – -$1.643
FY30$277.7M$277.7M – $277.7M$0.62$0.62 – $0.626

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.5×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.24%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+15.5%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-15.7%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 10.9M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.8% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β3.815-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 4 other (4 awards) in window

See when $AARD insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KShareholder voteAug 178-K — Item 5.07: Shareholder vote
AI summary

Aardvark Therapeutics, Inc. held its 2026 Annual Meeting on August 14, 2026, with 11,992,479 of 21,884,158 outstanding shares represented (54.79% quorum). Stockholders voted on three proposals as described in the proxy statement filed July 10, 2026. No specific vote results or proposal details were captured in the excerpt. Routine annual meeting disclosure; vote outcomes would indicate any contested director elections or say-on-pay concerns.

8-KOfficer or director changeJun 128-K — Item 5.02: Officer or director change
AI summary

Aardvark Therapeutics entered into a retention bonus agreement with CFO/COO Nelson Sun on June 10, 2026, committing to pay a total of $346,500: a $198,000 guaranteed annual bonus for 2026 and a $148,500 retention bonus, both payable on January 1, 2027 subject to continued employment. Termination without cause or resignation for good reason before that date triggers a pro-rated payout. Given the FDA clinical hold placed on ARD-101 (see separate filing), the retention package likely reflects the company's effort to stabilize leadership during a critical regulatory challenge.

424B5Prospectus supplement (offering)Apr 3424B5
8-KMaterial agreementMar 248-K — Item 1.01: Material agreement
S-3Shelf registrationMar 23S-3
+ 15 other (3 earnings 8-Ks · 2 10-Qs · 2 routine 8-Ks · 1 ARS) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AARDnewsfilecorp.com·13h agoAARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuitprnewswire.com·15h agoROSEN, NATIONAL TRIAL LAWYERS, Encourages Aardvark Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AARDglobenewswire.com·15h agoShareholders who lost money in shares of acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) should contact Wolf Haldenstein Immediatelyglobenewswire.com·19h agoDid You Lose Money Investing in Aardvark Therapeutics, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against AARDnewsfilecorp.com·21h ago

In themes

Explore the broader themes this ticker is being talked about under.

GLP-1 & Weight Loss

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALT$AURA$IOVA$NWBO$SLS$AMLX$ABCL
Voices on X · last 7 days

No standout posts about $AARD on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport